← Leaderboards
Daniel E Johnson
University Of Chicago
$10,482,584
Attributed
$14,202,793
Total exposure
11
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.8M · FY2005–23$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$14,202,793 · 11
By mechanism
R01$12,158,000 · 6
P50$1,965,955 · 2
M01$78,838 · 3
Top collaborators
- Jennifer R Grandis10 shared
- Katherine Ann Skorupski5 shared
Most similar at University Of Chicago
Same institution · by research overlap
- Timothy Kevin O'Connor$260,943
- Stacy Tessler Lindau$19,290,417
Others in their field
Top investigators on “Pathway Interactions”
- David Heimbrook · Leidos Biomedical Research, Inc.$202,777,247
- Ralph Parchment · Leidos Biomedical Research, Inc.$146,974,543
- David R. Weir · University Of Michigan At Ann Arbor$129,316,139
- Daniel Ernest Ford · Johns Hopkins University$108,075,637
- David W Simpson · University Of Southern California$88,046,235
- Charles D. Blanke · Oregon Health And Science University$86,571,896
Research focus
Pathway InteractionsMalignant NeoplasmsHead And Neck Squamous Cell CarcinomaTumorResistanceCellsCell LineProteinsIn VitroGrowthMouse ModelSignal PathwayHead And Neck CancerReportingClinical TrialsIn VivoApoptosisFoundationsInhibitor/AntagonistRadiation TherapyMediatingMalignant Epithelial CellPre-Clinical ModelExhibits
Grant awards (45)
PI3K Pathway Mutations in Head and Neck Cancer$641,113
R01 · FY2023 · DE
Targeting STAT3 to enhance anti-tumor immunity$636,402
R01 · FY2023 · DE · contact PI
PI3K Pathway Mutations in Head and Neck Cancer$634,703
R01 · FY2022 · DE
Targeting STAT3 to enhance anti-tumor immunity$630,039
R01 · FY2022 · DE · contact PI
PI3K Pathway Mutations in Head and Neck Cancer$641,113
R01 · FY2021 · DE
Targeting STAT3 to enhance anti-tumor immunity$636,402
R01 · FY2021 · DE · contact PI
PI3K Pathway Mutations in Head and Neck Cancer$645,333
R01 · FY2020 · DE
Targeting STAT3 to enhance anti-tumor immunity$636,402
R01 · FY2020 · DE · contact PI
Implications of Procaspase-8 Mutations in Oral Squamous Cell Carcinoma$395,174
R01 · FY2020 · DE · contact PI
PI3K Pathway Mutations in Head and Neck Cancer$648,229
R01 · FY2019 · DE
Targeting STAT3 to enhance anti-tumor immunity$633,201
R01 · FY2019 · DE · contact PI
Implications of Procaspase-8 Mutations in Oral Squamous Cell Carcinoma$395,187
R01 · FY2019 · DE · contact PI
Chemoprevention of Head & Neck Cancer$136,751
P50 · FY2019 · CA · contact PI
Implications of Procaspase-8 Mutations in Oral Squamous Cell Carcinoma$395,093
R01 · FY2018 · DE · contact PI
Chemoprevention of Head & Neck Cancer$125,123
P50 · FY2018 · CA · contact PI
Implications of Procaspase-8 Mutations in Oral Squamous Cell Carcinoma$398,264
R01 · FY2017 · DE · contact PI
Chemoprevention of Head & Neck Cancer$144,457
P50 · FY2017 · CA · contact PI
Implications of Procaspase-8 Mutations in Oral Squamous Cell Carcinoma$396,120
R01 · FY2016 · DE · contact PI
Chemoprevention of Head & Neck Cancer$153,906
P50 · FY2016 · CA · contact PI
Chemoprevention of Head & Neck Cancer$292,566
P50 · FY2015 · CA · contact PI
Molecular Targeting Strategies in HNSCC$295,784
R01 · FY2014 · CA · contact PI
INHIBITION OF THE STATS SIGNALING NETWORK$186,479
P50 · FY2014 · CA · contact PI
INHIBITION OF THE STATS SIGNALING NETWORK$291,782
P50 · FY2013 · CA · contact PI
Molecular Targeting Strategies in HNSCC$286,637
R01 · FY2013 · CA · contact PI
Molecular Targeting Strategies in HNSCC$304,932
R01 · FY2012 · CA · contact PI
INHIBITION OF THE STATS SIGNALING NETWORK$200,958
P50 · FY2012 · CA · contact PI
Molecular Targeting Strategies in HNSCC$304,932
R01 · FY2011 · CA · contact PI
INHIBITION OF THE STATS SIGNALING NETWORK$204,936
P50 · FY2011 · CA · contact PI
Molecular Targeting Strategies in HNSCC$314,363
R01 · FY2010 · CA · contact PI
INHIBITION OF THE STATS SIGNALING NETWORK$228,997
P50 · FY2010 · CA · contact PI
Opposing Roles for MEK/ERK in Differentiation & Leukemia$249,963
R01 · FY2009 · CA · contact PI
Opposing Roles for MEK/ERK in Differentiation & Leukemia$249,963
R01 · FY2008 · CA · contact PI
Opposing Roles for MEK/ERK in Differentiation & Leukemia$41,931
R01 · FY2008 · CA · contact PI
Opposing Roles for MEK/ERK in Differentiation & Leukemia$249,963
R01 · FY2007 · CA · contact PI
Opposing Roles for MEK/ERK in Differentiation & Leukemia$38,696
R01 · FY2007 · CA · contact PI
Opposing Roles for MEK/ERK in Differentiation & Leukemia$257,429
R01 · FY2006 · CA · contact PI
EXERCISE REHABILITATION FOR THE OLDER CANCER PATIENT$45,487
M01 · FY2006 · RR · contact PI
Opposing Roles for MEK/ERK in Differentiation &Leukemia$263,624
R01 · FY2005 · CA
Role of Cathepsin D in Chemotherapy Induced Cell Death$231,675
R01 · FY2005 · CA
EXERCISE REHABILITATION FOR THE OLDER CANCER PATIENT$572
M01 · FY2005 · RR
Role of Cathepsin D in Chemotherapy Induced Cell Death$234,360
R01 · FY2004 · CA
Role of Cathepsin D in Chemotherapy Induced Cell Death$3,000
R01 · FY2003 · CA
Role of Cathepsin D in Chemotherapy Induced Cell Death$235,463
R01 · FY2002 · CA
Role of Cathepsin D in Chemotherapy Induced Cell Death$232,510
R01 · FY2001 · CA
TRIAL OF RECOMBINANT INTERLEUKIN-2 IN SYMPTOMATIC HIV-INFECTED CHILDREN$32,779
M01 · FY2000 · RR